Polish cell therapy company PolTREG (WSE: PTG) has received a Current Good Manufacturing Practice (cGMP) certificate, allowing it to produce advanced therapies at its own facility.
Shares in the clinical-stage biotech, which is focused on cell therapies for a range of autoimmune diseases, ticked up around 3% on Monday morning.
The company is looking to lead in the area of T-regulatory cells (Tregs), with its most advanced candidate, PTG-007, in mid-stage testing for early-onset Type-1 diabetes (T1D).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze